PUBLIC COMPANY
save$IRONDisc Medicine, Inc.
$IRON64.51+1.41%Watertown, MA, USupdated 2d ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase3HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
- phase2Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- phase2Study of DISC-0974-201 in Participants With IBD and Anemia
- phase3Study of Bitopertin in Participants With EPP or XLP (APOLLO)
- —Expanded Access Program of Bitopertin For Participants With EPP or XLP
- phase1A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- phase1Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia
- phase2A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Insider activity
source: SEC Form 4🐶 Hiring Signal
Where Disc Medicine, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaHematology 13
News
- Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assetsLexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich ataxia (FA) portfolio while locking in three strategic collabora…fiercebiotech · 12d ago
- Kairon Health raises $5M to use data to make patients healthierA startup that helps value-based healthcare practices turn patient data into a to-do list for staff has raised new funding, Endpoints News learned exclusively. Kairon Health pulls together patient…endpoints · 19d ago
- Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded labelPlus news about Tevard Biosciences, InduPro, EMD Serono, Shionogi, Bayer's Hyrnuo. Disc's competitor for Takeda's blood disorder drug Mimrylo: Disc Medicine shared initial data from its Phase 2 RES…endpoints · 24d ago
- A booming business on Wall Street would love more biotechs to quietly dieOnce disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.biopharma_dive · 24d ago
- Opinion: John Fetterman’s post-stroke, politically problematic behaviors offer lessons about brain health on Capitol Hill“Nothing in the recent reporting about John Fetterman is medically surprising,” write Michael P.H. Stanley and Isaiah Kletenik.stat · 24d ago
- Ionis’ rare neurology drug approved; Pfizer inks an ADC dealZanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.biopharma_dive · 1mo ago
- FDA OKs Takeda, Protagonist drug for rare blood cancerThe clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.biopharma_dive · 1mo ago
- Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunityThe approval of rusfertide—now to be branded Mimrylo—for polycythemia vera marks a key win for Takeda, which now has crossed the FDA finish line for two of three critical product launches slated fo…biospace · 1mo ago
- FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood DisorderThe U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood c…fda_press · 1mo ago
- Amgen, academic centers weigh new FDA pilot to speed early drug trialsTo better combat China and Australia's dominance in expediting early-phase trials, the FDA and stakeholders are ironing out the details of a pilot program to accelerate first-in-human trials. Amgen…endpoints · 1mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that